Inozyme Pharma (INZY) Competitors $4.00 0.00 (0.00%) As of 07/1/2025 Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock INZY vs. ELVN, VERV, NTLA, COLL, AKBA, SYRE, MLYS, AVDL, PHVS, and NRIXShould you be buying Inozyme Pharma stock or one of its competitors? The main competitors of Inozyme Pharma include Enliven Therapeutics (ELVN), Verve Therapeutics (VERV), Intellia Therapeutics (NTLA), Collegium Pharmaceutical (COLL), Akebia Therapeutics (AKBA), Spyre Therapeutics (SYRE), Mineralys Therapeutics (MLYS), Avadel Pharmaceuticals (AVDL), Pharvaris (PHVS), and Nurix Therapeutics (NRIX). These companies are all part of the "pharmaceutical products" industry. Inozyme Pharma vs. Its Competitors Enliven Therapeutics Verve Therapeutics Intellia Therapeutics Collegium Pharmaceutical Akebia Therapeutics Spyre Therapeutics Mineralys Therapeutics Avadel Pharmaceuticals Pharvaris Nurix Therapeutics Enliven Therapeutics (NASDAQ:ELVN) and Inozyme Pharma (NASDAQ:INZY) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, analyst recommendations, risk, media sentiment, dividends, earnings, institutional ownership and profitability. Does the media favor ELVN or INZY? In the previous week, Enliven Therapeutics had 9 more articles in the media than Inozyme Pharma. MarketBeat recorded 13 mentions for Enliven Therapeutics and 4 mentions for Inozyme Pharma. Enliven Therapeutics' average media sentiment score of 0.69 beat Inozyme Pharma's score of 0.32 indicating that Enliven Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Enliven Therapeutics 4 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Inozyme Pharma 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more volatility & risk, ELVN or INZY? Enliven Therapeutics has a beta of 0.83, suggesting that its stock price is 17% less volatile than the S&P 500. Comparatively, Inozyme Pharma has a beta of 2.27, suggesting that its stock price is 127% more volatile than the S&P 500. Which has better valuation and earnings, ELVN or INZY? Enliven Therapeutics is trading at a lower price-to-earnings ratio than Inozyme Pharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEnliven TherapeuticsN/AN/A-$89.02M-$1.92-10.20Inozyme PharmaN/AN/A-$102.02M-$1.69-2.37 Do insiders & institutionals hold more shares of ELVN or INZY? 95.1% of Enliven Therapeutics shares are held by institutional investors. Comparatively, 88.3% of Inozyme Pharma shares are held by institutional investors. 25.9% of Enliven Therapeutics shares are held by insiders. Comparatively, 12.2% of Inozyme Pharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Is ELVN or INZY more profitable? Enliven Therapeutics' return on equity of -31.84% beat Inozyme Pharma's return on equity.Company Net Margins Return on Equity Return on Assets Enliven TherapeuticsN/A -31.84% -30.09% Inozyme Pharma N/A -159.93%-82.48% Do analysts recommend ELVN or INZY? Enliven Therapeutics currently has a consensus price target of $41.20, suggesting a potential upside of 110.31%. Inozyme Pharma has a consensus price target of $11.75, suggesting a potential upside of 193.75%. Given Inozyme Pharma's higher possible upside, analysts plainly believe Inozyme Pharma is more favorable than Enliven Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Enliven Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00Inozyme Pharma 0 Sell rating(s) 5 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.44 SummaryEnliven Therapeutics beats Inozyme Pharma on 9 of the 13 factors compared between the two stocks. Get Inozyme Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for INZY and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding INZY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart INZY vs. The Competition Export to ExcelMetricInozyme PharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$258.25M$2.91B$5.51B$9.02BDividend YieldN/A2.44%5.24%4.05%P/E Ratio-2.3720.4427.2120.09Price / SalesN/A190.28370.4792.99Price / CashN/A41.7026.2128.59Price / Book4.447.397.945.55Net Income-$102.02M-$55.04M$3.17B$248.49M7 Day PerformanceN/A2.51%1.79%4.87%1 Month Performance0.25%-0.21%1.27%6.63%1 Year Performance-13.04%3.41%33.56%20.38% Inozyme Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INZYInozyme Pharma3.3846 of 5 stars$4.00flat$11.75+193.8%N/A$258.25MN/A-2.3750Analyst UpgradeELVNEnliven Therapeutics2.6834 of 5 stars$20.06-3.0%$39.60+97.4%-12.6%$1.01BN/A0.0050VERVVerve Therapeutics3.4592 of 5 stars$11.23-0.6%$14.57+29.8%+112.6%$1.01B$32.33M0.00110NTLAIntellia Therapeutics4.7039 of 5 stars$9.38-1.9%$33.37+255.7%-55.0%$990.25M$57.88M-1.79600COLLCollegium Pharmaceutical4.2597 of 5 stars$29.57-1.2%$43.75+48.0%-4.0%$961.71M$631.45M24.24210News CoverageAnalyst DowngradeBuyback AnnouncementGap UpAKBAAkebia Therapeutics4.2343 of 5 stars$3.64-0.3%$6.75+85.4%+287.9%$958.62M$160.18M-17.33430SYRESpyre Therapeutics1.3354 of 5 stars$14.97-1.6%$53.40+256.7%-40.0%$917.39M$890K0.0073MLYSMineralys Therapeutics2.1338 of 5 stars$13.53-1.3%$32.25+138.4%+8.8%$893.55MN/A0.0028AVDLAvadel Pharmaceuticals2.435 of 5 stars$8.85-3.8%$18.17+105.3%-39.9%$890M$169.12M-32.7870PHVSPharvaris1.7646 of 5 stars$17.60+3.5%$36.20+105.7%+8.1%$888.93MN/A0.0030NRIXNurix Therapeutics1.6053 of 5 stars$11.39-2.1%$30.18+164.9%-36.5%$887.38M$54.55M0.00300Upcoming Earnings Related Companies and Tools Related Companies Enliven Therapeutics Alternatives Verve Therapeutics Alternatives Intellia Therapeutics Alternatives Collegium Pharmaceutical Alternatives Akebia Therapeutics Alternatives Spyre Therapeutics Alternatives Mineralys Therapeutics Alternatives Avadel Pharmaceuticals Alternatives Pharvaris Alternatives Nurix Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:INZY) was last updated on 7/8/2025 by MarketBeat.com Staff From Our PartnersEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredF1 Engineering Powers This Electric Marine MotorThe future of marine propulsion has arrived - powered by F-1 grade engineering. In collaboration with McLar...The Tomorrow Investor | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredForget Nvidia, This “Ghost Town” Company Holds the Key to the AI BoomCold War Discovery Could Unlock $100 Trillion in Wealth Jeff recently traveled to an American ghost town to...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inozyme Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Inozyme Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
